NEW YORK (GenomeWeb News) – BioView and Kindstar Global this week announced an agreement granting Kindstar an exclusive license to validate and implement BioView's test for the early detection of lung cancer.

BioView's test is based on fluorescent in situ hybridization technology. Under the deal, Kindstar will purchase equipment and kits from BioView and will exclusively perform the test in China, Macau, Hong Kong, and Taiwan.

Beijing-based Kindstar has already successfully carried out a pilot study using BioView's assay, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.